GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
NEW YORK, March 20, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Innocoll Holdings plc (“Innocoll”) (NASDAQ:INNL) between March 17, 2016 and December 29, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Eastern District of Pennsylvania. To get more information go to:
http://www.zlk.com/pslra/innocoll-holdings-plc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Innocoll’s New Drug Application (“NDA”) submission to the FDA in October 2016 for XARACOLL was incomplete; (2) due to the incomplete NDA submission, XARACOLL would not be approved in 2017 as investors were led to believe; and (3) as a result, Defendants’ statements about Innocoll’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
On December 29, 2016, Innocoll announced it had received a Refusal to File letter from the U.S. Food & Drug Administration with respect to XARACOLL.
If you suffered a loss in Innocoll you have until March 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
